High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes

Bone

Volumn 49, Issue 5, 2011, Pages 1010-1019

  Niziolek, Paul J ^a   Farmer, Takeisha L ^b   Cui, Yajun ^c   Turner, Charles H ^d   Warman, Matthew L ^e,f   Robling, Alexander G ^b,d  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Indiana University Purdue University Indianapolis   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

High bone mass; Lrp5; Sclerostin; Sost; Wnt

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; SCLEROSTIN; SEROTONIN; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE CHARACTERISTICS AND FUNCTIONS; BONE MASS; BONE SIZE; BONE STRENGTH; BONE STRUCTURE; CONTROLLED STUDY; CRANIAL NERVE; GAIN OF FUNCTION MUTATION; GENE; GENE MUTATION; GENETIC ANALYSIS; HIGH BONE MASS; KNOCKIN MOUSE; KNOCKOUT MOUSE; LOSS OF FUNCTION MUTATION; LRP5 GENE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PERIOSTEUM; PHENOTYPIC VARIATION; PROTEIN PROTEIN INTERACTION; SEROTONIN BLOOD LEVEL; SIGNAL TRANSDUCTION; SKULL; TIBIA; TRABECULAR BONE; ULNA;

ANIMALS; BIOMECHANICS; BONE DEVELOPMENT; MALE; MICE; MICE, MUTANT STRAINS; MUTATION; ORGAN SIZE; PHENOTYPE; SEROTONIN; SIGNAL TRANSDUCTION; TOMOGRAPHY, X-RAY COMPUTED; WNT PROTEINS;

EID: 80054839269     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.07.034     Document Type: Article

References (35)

1. Johnson M.L., Harnish K., Nusse R., Van Hul W. LRP5 and Wnt signaling: a union made for bone. J Bone Miner Res 2004, 19:1749-1757.
2. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523.
3. Ferrari S.L., Deutsch S., Choudhury U., Chevalley T., Bonjour J.P., Dermitzakis E.T., et al. Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. Am J Hum Genet 2004, 74:866-875.
4. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002, 70:11-19.
5. Van Wesenbeeck L., Cleiren E., Gram J., Beals R.K., Benichou O., Scopelliti D., et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 2003, 72:763-771.
6. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10:537-543.
7. Balemans W., Patel N., Ebeling M., Van Hul E., Wuyts W., Lacza C., et al. Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002, 39:91-97.
8. Staehling-Hampton K., Proll S., Paeper B.W., Zhao L., Charmley P., Brown A., et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 2002, 110:144-152.
9. Beighton P., Cremin B.J., Hamersma H. The radiology of sclerosteosis. Br J Radiol 1976, 49:934-939.
10. Beighton P., Durr L., Hamersma H. The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals. Ann Intern Med 1976, 84:393-397.
11. Gardner J.C., van Bezooijen R.L., Mervis B., Hamdy N.A., Lowik C.W., Hamersma H., et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 2005, 90:6392-6395.
12. Li X., Zhang Y., Kang H., Liu W., Liu P., Zhang J., et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005, 280:19883-19887.
13. Semenov M., Tamai K., He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005, 280:26770-26775.
14. Semenov M.V., He X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem 2006, 281:38276-38284.
15. Ellies D.L., Viviano B., McCarthy J., Rey J.P., Itasaki N., Saunders S., et al. Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 2006, 21:1738-1749.
16. Cui Y., Niziolek P.J., MacDonald B.T., Zylstra C.R., Alenina N., Robinson D.R., et al. Lrp5 functions in bone to regulate bone mass. Nat Med 2011, 17:684-691.
17. Li X., Ominsky M.S., Niu Q.T., Sun N., Daugherty B., D'Agostin D., et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008, 23:860-869.
18. Yadav V.K., Ryu J.H., Suda N., Tanaka K.F., Gingrich J.A., Schutz G., et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135:825-837.
19. Sawakami K., Robling A.G., Ai M., Pitner N.D., Liu D., Warden S.J., et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 2006, 281:23698-23711.
20. Robling A.G., Hinant F.M., Burr D.B., Turner C.H. Improved bone structure and strength after long-term mechanical loading is greatest if loading is separated into short bouts. J Bone Miner Res 2002, 17:1545-1554.
21. Schriefer J.L., Robling A.G., Warden S.J., Fournier A.J., Mason J.J., Turner C.H. A comparison of mechanical properties derived from multiple skeletal sites in mice. J Biomech 2005, 38:467-475.
22. Turner C.H., Burr D.B. Basic biomechanical measurements of bone: a tutorial. Bone 1993, 14:595-608.
23. Ai M., Holmen S.L., Van Hul W., Williams B.O., Warman M.L. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol 2005, 25:4946-4955.
24. Zhang Y., Wang Y., Li X., Zhang J., Mao J., Li Z., et al. The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd. Mol Cell Biol 2004, 24:4677-4684.
25. Balemans W., Piters E., Cleiren E., Ai M., Van Wesenbeeck L., Warman M.L., et al. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif Tissue Int 2008, 82:445-453.
26. Leupin O., Piters E., Halleux C., Hu S., Kramer I., Morvan F., et al. Bone overgrowth-associated mutations in LRP4 impair sclerostin-facilitator function. J Biol Chem 2011, 286:19489-19500.
27. Weatherbee S.D., Anderson K.V., Niswander L.A. LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. Development 2006, 133:4993-5000.
28. Choi H.Y., Dieckmann M., Herz J., Niemeier A. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS One 2009, 4:e7930.
29. Babij P., Zhao W., Small C., Kharode Y., Yaworsky P.J., Bouxsein M.L., et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 2003, 18:960-974.
30. Akhter M.P., Wells D.J., Short S.J., Cullen D.M., Johnson M.L., Haynatzki G.R., et al. Bone biomechanical properties in LRP5 mutant mice. Bone 2004, 35:162-169.
31. Beighton P., Hamersma H. Ophthalmological complications in the sclerosing bone dysplasias. Ophthalmic Paediatr Genet 1985, 6:129-134.
32. Hamersma H., Gardner J., Beighton P. The natural history of sclerosteosis. Clin Genet 2003, 63:192-197.
33. Hamersma H., Hofmeyr L. Too much bone: the middle ear in sclerosing bone dysplasias. Adv Otorhinolaryngol 2007, 65:61-67.
34. Nager G.T., Hamersma H. Sclerosteosis involving the temporal bone: histopathologic aspects. Am J Otolaryngol 1986, 7:1-16.
35. Stephen L.X., Hamersma H., Gardner J., Beighton P. Dental and oral manifestations of sclerosteosis. Int Dent J 2001, 51:287-290.